Life Length® receives prize for best Spanish start-up in Technology and Innovation | Life Length

Life Length® receives prize for best Spanish start-up in Technology and Innovation

Life Length<span class="superindice">®</span> receives prize for best Spanish start-up in Technology and Innovation

05 Jun Life Length® receives prize for best Spanish start-up in Technology and Innovation

Life Length® , the world’s leading telomere testing company has received the prize for best Spanish start-up in Technology and Innovation for developing and commercializing a unique technique to measure telomeres. The prize has been awarded by IX Premios Pyme Expansión (Spain’s leading business newspaper) together with Ifema (Madrid’s trade fair institution), Sanitas (Spain’s leading medical insurance company) and the Spanish National Postal Service. Life Length commercializes its Telomere Analysis Technology (TAT) developed at the Spanish National Cancer Research Centre (CNIO in Spanish) in Madrid, Spain. Life Length has an exclusive license agreement with Spanish Government for the technology which comprises different established protocols that allow the determination of telomere length in individual cells, both from cellular (blood) and tissue samples. Telomeres are essential to preserve the regenerative capacity of different tissues and organs and significantly contribute to aging when they become short. There is extensive scientific evidence showing the strong correlation between the percentage of short telomeres and the risk of developing diseases associated with aging (including cancer, cardiovascular diseases, neurological disorders, among others. No other technique is able to measure telomeres with such granularity and precision. Stephen J. Matlin, CEO, Life Length said, “We are delighted to receive this prize which recognizes both the quality of the science behind our technology as well as our business model which has allowed us to develop the best telomere test in the world in such a short time. We are convinced that it will become a standard test for checkups and preventative and personalized medicine. We have already partnered with laboratories for clinical analysis in more than 10 countries.” Mr. Matlin continued, “Our test has a huge potential to grow, similar to what happened with cholesterol testing in the 80’s. We offer our services from Spain through our national and international partners to three types of markets: Individuals (always through physicians), research (basic research centers in such fields as oncology, neurology, cardiology, infertility, among others) and developing products (R&D departments: cosmetics, nutraceuticals, pharma, biotech, etc.) Also, we are partners in several academic research programs focused on neurodegenerative diseases with the WHO and 18 other universities and European groups.

 

No Comments

Post A Comment